Researcher Spotlight: Niloufer Khan, MD, MS Memorial Sloan Kettering Cancer Center Cutaneous T-cell lymphoma (CTCL) is a type of skin lymphoma usually managed as a chronic disease without a standard frontline therapy, and treatment plans typically vary from patient to patient.…
Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphomawho have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse after…
Researcher Spotlight: Patrizia Mondello, MD, PhD Mayo Clinic, Rochester Follicular lymphoma (FL) is generally slow-growing cancerwith an overall favorable prognosis. One subset, known asFL3B, has a distinctly worse clinical outcome with limited treatment options. The same treatments used to manage the other,…
Researcher Spotlight: Coraline Mlynarczyk, PhD Joan & Sanford I. Weill Medical College of Cornell University Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous B-cell malignancy, with each patient presenting with a heavy and diverse burden of alterations in their DNA. Therefore,…
Researcher Spotlight: Rossella Marullo, MD, PhD Joan & Sanford I. Weill Medical College of Cornell University Two genomic studies revealed that 8 to 16 percent of diffuse large B-cell lymphoma (DLBCL) patients harborloss-of-function mutations in the gene TOX (TOXLOF). TOX is a…
Researcher Spotlight: Zachary Epstein-Peterson, MD Memorial Sloan Kettering Cancer Center In recent years, several new therapies have been investigated for treating T-cell lymphomas. Some of thesemedicines work in up to 50 percent of patients whoselymphoma has relapsed or has not responded to…
Researcher Spotlight: Tomohiro Aoki, PhD British Columbia Cancer Research Centre Hodgkin lymphoma (HL) treatment relies on multimodality treatment with standard chemotherapy,radiation therapy, and autologous or allogeneic stem celltransplantation in cases of relapsed disease. For his LRFresearch project, Dr. Tomohiro Aoki aims to…
Researcher Spotlight: Suchitra Sundaram, MD The Mount Sinai Icahn School of Medicine Over the past several years, targeted therapy with small molecule inhibitors and antibodies has replaced chemotherapy as the standard treatment for patients with chronic lymphocytic leukemia (CLL). Despite…
Researcher Spotlight: Jason Romancik, MD Emory University – Winship Cancer Institute Follicular lymphoma (FL) is typically a slow-growingor indolent form of non- Hodgkin lymphoma (NHL)that arises from B-lymphocytes, making it a B-celllymphoma. FL is generally very responsive to radiationand chemotherapy, and most…
Researcher Spotlight: Erin Mulvey, MD Weill Cornell Medical College Diffuse large B-cell lymphoma (DLBCL) and follicularlymphoma (FL) are the two most common types of non-Hodgkin lymphoma, with one categorized as aggressive (fast-growing) and one considered indolent (slow-growing), respectively.First-line treatment for DLBCL…